STUDY: Chronic pain sufferers choosing cannabis

Study suggests main reasons for switch to cannabis from prescribed meds due to reduced side effects

Chronic pain sufferers and those taking mental health meds would rather turn to cannabis instead of their prescribed opioid medication, according to new research by the University of British Columbia and University of Victoria.

“This study is one of the first to track medical cannabis use under the new system of licensed producers, meaning that all participants had physician authorization to access cannabis in addition to their prescription medicines,” said UBC Assoc. Prof. Zach Walsh, co-author of the study.

The study tracked more than 250 patients with prescribed medical cannabis—people treated for conditions such as chronic pain, mental health and gastrointestinal issues. Overall, 63 per cent of respondents reported using cannabis instead of their prescription drugs, which included opioids (to treat pain), benzodiazepines (sedatives) and anti-depressants.

Study lead Philippe Lucas is vice-president of Patient Research and Access at Tilray, a federally authorized medical cannabis production and research company, and a graduate fellow at the University of Victoria Centre for Addictions Research of B.C.

Lucas suggests the main reasons for the switch to cannabis from prescribed meds is due to reduced side effects, better symptom management and a feeling that cannabis is safer than prescription drugs.

Walsh goes on to suggest cannabis may have an important role to play in addressing the problematic use of pharmaceutical medications such as opioids.

In 2001, Canada became one of the first nations to develop a program to allow access to cannabis for medical purposes. As of August 2016 more than 30 federally authorized licensed producers of cannabis provided product to more than 65,000 patients.

“Further research into how well cannabis works compared to the accepted front-line treatments is warranted,” says Walsh. “Additionally, long-term research into the potential impact of the cannabis substitution on the quality of patient’s lives is ongoing.”

The study, published in International Journal of Drug Policy, was funded by Tilray.

Just Posted

Kelowna council defers decision on homeless development

BC Housing is revisiting original plan after concerns from local businesses

3% tax hike proposed in West Kelowna

Proposed provisional budget tax hike in line with recent annual increases in the city

Okanagan robbery suspect sought

RCMP are seeking the public’s assistance in identifying a suspect in an… Continue reading

11-year-old water quality advisory lifted in Glenmore

Glenmore-Ellison Improvement District says Interior Health gave the green light to lift advisory

Site C dam goes ahead, cost estimate now up to $10.7 billion

Premier John Horgan says Christy Clark left him no other choice

Crook’s Corner

A slice of this week’s arts and entertainment happenings in the North Okanagan at a glance

Six-year-old boy needs $19,000 a month to treat rare form of arthritis

Mother of sick Sooke boy asks government to help fund treatments

Environmental groups slam NDP decision to continue with Site C

Construction industry, meanwhile, is cautiously optimistic about how the project will look

Be ladder safe both at work and home

WorkSafeBC wants you to keep safe while hanging those Christmas lights this year

B.C. overdose deaths surpass 1,200

96 people died of illicit drug overdoses in October

A classic Christmas play with a Kelowna twist

Scrooge is transported to Kelowna in New Vintage Theatre’s new holiday play, opening Wednesday

Crown appeals stay against Jamie Bacon in Surrey Six killings

B.C.’s prosecution service says judge’s decision reveals ‘errors of law’

Feds agree to give provinces 75 per cent of pot tax revenues

Finance Minister Bill Morneau announced the agreement today

Attempted murder charge up in the air after victim’s death

Without Thomas Szajko’s testimony, alleged shooter Afshin Ighani could get off on that charge

Most Read